Catalyst Dossier · compiled by CeliA 🧫

Idorsia Pharmaceuticals Ltd. (IDIA)

Healthcare · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-27 (est.)

PDUFA

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-12-27 (est.)PDUFA · BOND-003imp 8/10

Pipeline

Asset	Phase	Indication
Daridorexant 10 mg	Phase 3	Insomnia Disorder
ACT-541468 5 mg	Phase 2	Insomnia Disorder
ACT-709478 for oral use	Phase 2	Photosensitive Epilepsy
Aprocitentan 5 mg	Phase 2	Essential Hypertension
Clazosentan 1 mg/h	Phase 2	Aneurysmal Subarachnoid Hemorrhage
ACT-541468	Phase 2	Insomnia Disorder
ACT-774312	Phase 2	Bilateral Nasal Polyposis
ACT-280778	Phase 2	Essential Hypertension
Daridorexant	Phase 3	Insomnia Disorder
Cetirizine	Phase 3	Seasonal Allergic Rhinitis
ACT-539313	Phase 2	Binge-Eating Disorder
Aprocitentan 12.5 mg	Phase 3	Resistant Hypertension
Lucerastat	Phase 3	Fabry Disease
Clazosentan	Phase 3	Aneurysmal Subarachnoid Hemorrhage
tezosentan	Phase 3	Acute Heart Failure
Setipiprant	Phase 2	Asthma
Daridorexant 50 mg	Phase 3	Insomnia Disorder
Zolpidem	Phase 2	Insomnia Disorder
Daridorexant 25 mg	Phase 3	Insomnia
ACT-129968	Phase 3	Seasonal Allergic Rhinitis

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IDIA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.